Zenas BioPharma, Inc. (ZBIO)
NASDAQ: ZBIO · Real-Time Price · USD
31.99
-0.44 (-1.36%)
At close: Aug 10, 2026, 4:00 PM EDT
31.99
0.00 (0.00%)
After-hours: Aug 10, 2026, 4:10 PM EDT
Zenas BioPharma Stock Forecast
Stock Price Forecast
According to 8 analysts polled by S&P Global, Zenas BioPharma stock has a consensus rating of "Strong Buy" and an average price target of $43.5. The average 1-year stock price forecast is 35.98% higher than the current stock price, while the lowest is $22 (-31.23%) and the highest is $59 (+84.43%).
Price Target: $43.5 (+35.98%)
Analyst Consensus: Strong Buy
Price Target
Chart* Price targets were last updated on Jun 26, 2026.
Analyst Ratings
The average analyst rating for Zenas BioPharma stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Feb '26 | Mar '26 | Apr '26 | May '26 | Jun '26 | Jul '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 7 | 7 | 7 | 7 | 7 | 7 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 8 | 8 | 8 | 8 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $44 | Buy | Reiterates | $44 | +37.54% | Jun 26, 2026 |
| Guggenheim | Guggenheim | Buy Maintains $55 | Buy | Maintains | $55 | +71.93% | Jun 5, 2026 |
| Morgan Stanley | Morgan Stanley | Hold Maintains $21 → $22 | Hold | Maintains | $21 → $22 | -31.23% | May 14, 2026 |
| Wedbush | Wedbush | Buy Maintains $45 | Buy | Maintains | $45 | +40.67% | May 14, 2026 |
| Citi | Citi | Buy Reiterates $41 | Buy | Reiterates | $41 | +28.17% | May 14, 2026 |
Financial Forecast
Revenue This Year
36.26M
from 10.00M
Increased by 262.60%
Revenue Next Year
63.75M
from 36.26M
Increased by 75.81%
EPS This Year
-4.30
from -4.83
EPS Next Year
-2.27
from -4.30
EPS and Forward PE are based on non-GAAP adjusted numbers.